Search results for "treatment failure"

showing 10 items of 114 documents

Interim 18f-PDGPET for Aggressive Non-Hodgking's Lymphoma: A Systematic Review and Meta-Analysis

2011

Abstract Abstract 5183 Background: The advantage of using interim 18F-fluorodeoxyglucose (FDG) positron-emission tomography (PET) scan in the clinical work-up of patients with non-Hodgkin's lymphoma (NLH) is unclear. Data from meta-analyses are inconclusive, mainly because of the low number of patients evaluated and heterogeneity among studies. New clinical investigations, focused on this topic, have been recently published. We conducted an updated systematic review on the role of 18PDG-PET for the interim evaluation in patients with aggressive lymphomas. Materials and Methods: Medline, Embase, Scopus and Databases were searched for relevant studies through March 2011. We included studies t…

Contingency tablemedicine.medical_specialtybusiness.industryImmunologyMEDLINECell BiologyHematologymedicine.diseaseBiochemistryChemotherapy regimenTreatment failureLymphomaMeta-analysisInternal medicineInterimMedicineNuclear medicinebusinessDiffuse large B-cell lymphomaBlood
researchProduct

Predictors of therapy failure in newly diagnosed pulmonary tuberculosis cases in Beira, Mozambique.

2018

Abstract Objective Tuberculosis (TB) remains a major global health issue, ranking in the top ten causes of death worldwide. A deep understanding of factors influencing poor treatment outcomes may allow the development of additional treatment strategies, focused on the most vulnerable groups. Aims of the study were: (i) to evaluate the treatment outcome among TB subjects followed in an outpatient setting and (ii) to analyze factors associated with treatment failure in newly diagnosed patients with pulmonary TB in Beira, the second largest city of Mozambique. Results A total of 301 TB adult patients (32.6% females) were enrolled. Among them, 62 (20.6%) experienced a treatment failure over a 6…

Genetics and Molecular Biology (all)0301 basic medicineMaleTreatment outcomeAntitubercular Agentslcsh:MedicineHIV InfectionsSettore MED/42 - Igiene Generale E ApplicataBiochemistryTreatment failureBody Mass Index0302 clinical medicineTherapy failureOutpatientsGlobal healthOdds Ratio030212 general & internal medicineTreatment Failurelcsh:QH301-705.5MozambiqueCoinfectionGeneral MedicinePrognosisMozambique; Therapy failure; Tuberculosis; Biochemistry Genetics and Molecular Biology (all)Research NoteEducational StatusFemaleAdultEmploymentmedicine.medical_specialtyTuberculosisAdolescent030106 microbiologyNewly diagnosedGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesPulmonary tuberculosisInternal medicinemedicineHumansTuberculosislcsh:Science (General)PovertyTuberculosis PulmonaryAdult patientsbusiness.industrylcsh:RMalnutritionmedicine.diseaseTuberculosis Mozambique Therapy failurelcsh:Biology (General)Hiv statusbusinesslcsh:Q1-390BMC research notes
researchProduct

Can bone marrow-derived multipotent adult progenitor cells regenerate infarcted myocardium?

2006

Objectives: To assess the functional effects of multipotent adult progenitor cells (MAPCs) transplanted in a rat model of chronic myocardial infarction. Methods: Forty-four rats underwent coronary ligation and, 14 days later, were randomly allocated to receive in-scar injections (5×106 cells/150 μL) of green fluorescent protein (eGFP)-transduced allogeneic MAPCs ( n =25) or culture medium (controls, n =19). Nine of the MAPC-treated hearts were employed for functional studies while the remaining 16 received cells co-labeled with Resovist™ and were only used for serial histological assessments. Left ventricular (LV) function was assessed echocardiographically before transplantation and 1 mont…

Graft RejectionPathologymedicine.medical_specialtyEndotheliumPhysiologyMyocardial InfarctionBone Marrow CellsRats Sprague-DawleyPhysiology (medical)MedicineAnimalsMyocardial infarctionTreatment FailureProgenitor cellbusiness.industryMultipotent Stem CellsMyocardiummedicine.diseaseMyocardial ContractionRatsTransplantationmedicine.anatomical_structureMultipotent Stem CellModels AnimalImmunohistochemistryFemaleBone marrowStem cellCardiology and Cardiovascular MedicinebusinessCardiovascular research
researchProduct

Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient dat…

2002

Background and aims: Retreatment with a combination of α interferon (IFN) plus ribavirin of patients with chronic hepatitis C who did not respond to IFN monotherapy has not been assessed in large controlled studies. Methods: To assess the effectiveness and tolerability of IFN/ribavirin retreatment of non-responders to IFN and to identify predictors of complete (biochemical and virological) sustained response, we performed a meta-analysis of individual data on 581 patients from 10 centres. Retreatment with various IFN schedules (mean total dose 544 mega units) and a fixed ribavirin dose (1000–1200 mg/daily depending on body weight) was given for 24–60 (mean 39.5) weeks. Results: Biochemical …

HCV interferon ribavirinAdultMalemedicine.medical_specialtyCombination therapymedicine.medical_treatmentAlpha interferonGastroenterologyAntiviral AgentsDrug Administration Schedulechemistry.chemical_compoundDrug TherapyInternal medicineRibavirinmedicineHumansImmunologic FactorsTreatment FailureChronicAdverse effectChemotherapyAdult; Antiviral Agents; Chi-Square Distribution; Drug Administration Schedule; Drug Therapy; Combination; Female; Hepatitis C; Chronic; Humans; Immunologic Factors; Interferon-alpha; Logistic Models; Male; Middle Aged; Ribavirin; Treatment Failure; gamma-GlutamyltransferaseChi-Square Distributionbusiness.industryRibavirinLiver DiseaseGastroenterologyInterferon-alphaHepatitis Cgamma-GlutamyltransferaseHepatitis C ChronicMiddle Agedmedicine.diseaseHepatitis CConfidence intervalhumanitiesSurgeryLogistic ModelschemistryTolerabilityCombinationDrug Therapy CombinationFemalebusiness
researchProduct

Induction of interferon regulatory factors, 2′‐5′ oligoadenylate synthetase, P68 kinase and RNase L in chronic myelogenous leukaemia cells and its re…

1996

The genes crucially determining the therapeutic response of chronic myelogenous leukaemia (CML) to interferon-alpha (IFN-alpha) are unknown. Recently, two independent IFN-alpha signalling pathways were identified: the classic pathway mediates induction of 2'-5' oligoadenylate synthetase (2-5 OAS), p68 kinase and IFN regulatory factor-2 (IRF-2), whereas the alternate pathway leads to activation of IFN regulatory factor-1 (IRF-1). We investigated whether deficient or imbalanced expression of components of these two pathways is associated with resistance of CML cells to antiproliferative action of IFN alpha/beta. Constitutive and IFN-induced transcript levels of IFN-dependent genes in mononucl…

Interferon Regulatory Factor 2T-LymphocytesCellular differentiationmedicine.medical_treatmentProtein Serine-Threonine KinaseseIF-2 KinaseLeukemia Myelogenous Chronic BCR-ABL PositiveEndoribonucleases2'5'-Oligoadenylate SynthetasemedicineHumansRNA MessengerTreatment FailureInterferon alfaEIF-2 kinasebiology2'-5'-OligoadenylateInterferon-alphaHematologyBlotting NorthernHematopoietic Stem CellsPhosphoproteinsDNA-Binding ProteinsGene Expression Regulation NeoplasticRepressor ProteinsCytokineIRF1Cancer researchbiology.proteinInterferon Regulatory Factor-2GranulocytesInterferon Regulatory Factor-1Transcription Factorsmedicine.drugInterferon regulatory factorsBritish Journal of Haematology
researchProduct

Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel

2017

Abstract Hepatitis C virus (HCV) infection remains one of the main causes of chronic liver disease worldwide. The advent of direct-acting antivirals (DAAs) has significantly improved the course of patients with chronic HCV infection (CHC), due to the ability of these drugs to achieve high rates of sustained virological response (SVR). These exceedingly high rates of SVR and the excellent safety data have been confirmed in real life practice. Evolving guidelines have been issued by national and international scientific societies in accordance with the progression of clinical knowledge and the availability of new DAAs. These recommendations, however, may not be applied universally because of …

Liver CirrhosisDirect-acting antiviral agentFibrosiHepacivirusChronic liver diseasemedicine.disease_causeClinical knowledgeVirological response0302 clinical medicine80 and over030212 general & internal medicineChronicAntiviral treatment; Cirrhosis; Direct-acting antiviral agents; Hepatitis C; RAV; Treatment failureAged 80 and overGastroenterologyAntiviral treatment; Cirrhosis; Direct-acting antiviral agents; Hepatitis C; RAV; Treatment failure; Hepatology; GastroenterologyHepatitis CMiddle AgedViral LoadSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CCirrhosisItalyLiverCombination030211 gastroenterology & hepatologyDrug Therapy CombinationHumanAdultmedicine.medical_specialtyConsensusHepatitis C virusLiver CirrhosiConsensuAntiviral AgentsUnmet needs03 medical and health sciencesYoung AdultDrug TherapyInternal medicinemedicineHumansIntensive care medicineAgedAntiviral AgentHepaciviruCirrhosiHepatologybusiness.industryHepatologyHepatitis C Chronicmedicine.diseaseVirologyFibrosisAntiviral treatmentTreatment failurePosition paperAntiviral treatment; Cirrhosis; Direct-acting antiviral agents; Hepatitis C; RAV; Treatment failure; Adult; Aged; Aged 80 and over; Antiviral Agents; Consensus; Drug Therapy Combination; Fibrosis; Hepacivirus; Hepatitis C Chronic; Humans; Italy; Liver; Liver Cirrhosis; Middle Aged; Viral Load; Young AdultDirect-acting antiviral agentsRAVbusiness
researchProduct

Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. : Triple therapy in HCV geno…

2014

International audience; BACKGROUND & AIMS: We investigated the effectiveness of the protease inhibitors peginterferon and ribavirin in treatment-experienced patients with hepatitis C virus (HCV) genotype 1 infection and cirrhosis. METHODS: In the Compassionate Use of Protease Inhibitors in Viral C Cirrhosis study, 511 patients with HCV genotype 1 infection and compensated cirrhosis who did not respond to a prior course of peginterferon and ribavirin (44.3% relapsers or patients with viral breakthrough, 44.8% partial responders, and 8.0% null responders) were given either telaprevir (n = 299) or boceprevir (n = 212) for 48 weeks. We assessed percentages of patients with sustained viral respo…

Liver CirrhosisMaleCirrhosisComorbidityHepacivirusmedicine.disease_causeGastroenterologyPolyethylene GlycolsTelaprevirCohort Studieschemistry.chemical_compound0302 clinical medicinePegylated interferonboceprevirProspective StudiesTreatment FailureAged 80 and overGastroenterologyMiddle AgedRecombinant Proteins3. Good healthTreatment Outcome030220 oncology & carcinogenesisDrug Therapy CombinationFemale030211 gastroenterology & hepatologyOligopeptidesmedicine.drugAdultmedicine.medical_specialtyGenotypeProlineHepatitis C virusAntiviral Agents03 medical and health sciencesBoceprevirInternal medicineRibavirinmedicinechronic hepatitis CHumanstelaprevirAdverse effect[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyAgedHepatologybusiness.industrycirrhosisRibavirinInterferon-alphaOdds ratioHepatitis C Chronicmedicine.diseasechemistryMultivariate AnalysisImmunologybusinessFollow-Up StudiesGastroenterology
researchProduct

Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C.

2011

Background & Aims Chronic hepatitis C (CHC) and liver fibrosis progress more rapidly in men and menopausal women than in women of reproductive age. We investigated the associations among menopause, sustained virologic response (SVR), and liver damage in patients with CHC. Methods We performed a prospective study of 1000 consecutive, treatment-naive patients 18 years of age and older with compensated liver disease from CHC. Liver biopsy samples were analyzed (for fibrosis, inflammation, and steatosis) before patients received standard antiviral therapy. From women (n = 442), we collected data on the presence, type, and timing of menopause; associated hormone and metabolic features; serum lev…

Liver CirrhosisMaleTime Factorsmedicine.medical_treatmentBiopsyMenopause PrematuremenopauseHepacivirusmedicine.disease_causeGastroenterologySeverity of Illness IndexRisk FactorsOdds RatioProspective StudiesTreatment FailureProspective cohort studymedicine.diagnostic_testGastroenterologyAge FactorsHormone replacement therapy (menopause)Hepatitis CMiddle AgedViral LoadImmunohistochemistryMenopauseItalyLiver biopsyRNA ViralFemaleInflammation Mediatorshcv svr menopauseViral loadAdultmedicine.medical_specialtyantiviral therapy; menopause; prognostic factors; hcv therapyGenotypeHepatitis C virusAntiviral AgentsRisk AssessmentSex FactorsInternal medicinehcvmedicineHumanshcv; ifn; menopauseHepatologybusiness.industryInterleukin-6Tumor Necrosis Factor-alphaOdds ratioHepatitis C Chronicmedicine.diseaseifnEndocrinologyLogistic ModelsbusinessBiomarkersGastroenterology
researchProduct

Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: A decision tree for clini…

2009

Objective To survey rheumatologists' preferences for the choice of a second-line disease-modifying antirheumatic drug (DMARD) after inadequate response with methotrexate (MTX) therapy in rheumatoid arthritis (RA). Methods Thirty-six rheumatologists stated their preferences for RA treatment after inadequate response with MTX therapy (optimal dose at least 6 months). From the initial scenario, we derived 54 vignettes varying by rheumatoid factor or anti–cyclic citrullinated peptide antibody presence, swollen joint count, Disease Activity Score in 28 joints, and structural damage. Respondents stated their preference among 5 therapeutic options: MTX continuation, switch to another conventional …

MESH: Antirheumatic AgentsMESH: Decision TreesMESH: Treatment FailureArthritisMESH: Antibodies Anti-IdiotypicMESH: Logistic ModelsLogistic regressionSeverity of Illness IndexArthritis Rheumatoid0302 clinical medicineimmune system diseasesImmunology and AllergyMESH: Data CollectionPharmacology (medical)Treatment Failure030212 general & internal medicinePractice Patterns Physicians'skin and connective tissue diseasesMESH: Arthritis RheumatoidData CollectionAntibodies Anti-Idiotypic3. Good healthMESH: Interleukin 1 Receptor Antagonist ProteinMESH: Methotrexate[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemAntirheumatic AgentsRheumatoid arthritismedicine.drugmusculoskeletal diseasesmedicine.medical_specialtyMESH: Rheumatoid FactorImmunologyPeptides Cyclic03 medical and health sciencesRheumatologyRheumatoid FactorMESH: Severity of Illness IndexInternal medicineSeverity of illnessmedicineHumansRheumatoid factorMESH: Physician's Practice PatternsMESH: Peptides Cyclic030203 arthritis & rheumatologyAnakinraMESH: HumansTumor Necrosis Factor-alphabusiness.industryDecision Treesmedicine.diseaseRheumatologyInterleukin 1 Receptor Antagonist ProteinLogistic ModelsMethotrexateMESH: Tumor Necrosis Factor-alphaPhysical therapyMethotrexatebusinessArthritis & Rheumatism
researchProduct

Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months' fi…

2006

International audience; BACKGROUND: The objective was to develop a clinical practice format for choosing a second-line disease-modifying anti-rheumatic drug (DMARD) after a 6-month course of a first-line DMARD in patients with early RA. METHODS: A panel of 34 experts selected treatment option from various scenarios using the Thurstone pairwise method. The experts had to choose between two proposed DMARDs without proposing other options. The scenarios were obtained using the three items: DAS28, rheumatoid factor status and radiographic structural damage. A sample of 240 among 480 scenarios for each expert was taken at random. Responses given by at least 20% of the experts were considered per…

MESH: Antirheumatic AgentsMESH: Treatment FailureDiseaseReceptors Tumor Necrosis FactorEtanerceptArthritis Rheumatoid0302 clinical medicineMESH: Practice Guidelines as Topic030212 general & internal medicineTreatment Failureskin and connective tissue diseasesMESH: Immunoglobulin GMESH: Arthritis RheumatoidAnti rheumatic drugs3. Good healthClinical PracticeMESH: Methotrexate[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemRheumatoid arthritisAntirheumatic AgentsPractice Guidelines as TopicDrug Therapy CombinationLeflunomidemusculoskeletal diseasesmedicine.medical_specialtyMESH: Rheumatoid FactorFirst lineMESH: Drug Administration ScheduleDrug Administration ScheduleDecision Support Techniques03 medical and health sciencesRheumatologyRheumatoid FactorDmard therapymedicineRheumatoid factorHumansIntensive care medicine030203 arthritis & rheumatologyMESH: HumansMESH: Sulfasalazinebusiness.industryMESH: Biological MarkersMESH: Decision Support TechniquesEarly rheumatoid arthritisIsoxazolesmedicine.diseaseMESH: Receptors Tumor Necrosis FactorRadiographySulfasalazineMESH: Drug Therapy CombinationMethotrexateMESH: IsoxazolesImmunoglobulin GPhysical therapybusinessBiomarkersJoint bone spine
researchProduct